COVID-19-ის ვაქცინა: განსხვავება გადახედვებს შორის

|'''Oxford–AstraZeneca COVID-19 vaccine''' <small>(Vaxzevria, Covishield)</small><wbr /><ref>{{#invoke:Cite web| | title=Vaxzevria (previously COVID-19 Vaccine AstraZeneca) EPAR | website=[[European Medicines Agency]] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca }}</ref>{{efn-la|[[Serum Institute of India]] will be producing the ''ChAdOx1{{nbs}}nCoV-19'' vaccine for India<ref>{{cite news|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazeneca-serum-institute-of-india-sign-licensing-deal-for-1-billion-doses-of-oxford-vaccine/articleshow/76202016.cms|title=AstraZeneca & Serum Institute of India sign licensing deal for 1 million doses of Oxford vaccine|work=The Economic Times|access-date=15 June 2020}}</ref> and other low- and middle-income countries.<ref>{{cite news |title=Covid-19 vaccine: Serum Institute signs up for 100 million doses of vaccines for India, low and middle-income countries |url=https://www.financialexpress.com/lifestyle/health/covid-19-vaccine-serum-institute-signs-up-for-100-million-doses-of-vaccines-for-india-low-and-middle-income-countries/2047884/ |work=The Financial Express |date=7 August 2020}}</ref>}}{{efn-la|Oxford name: ''ChAdOx1 nCoV-19''. Manufacturing in Brazil to be carried out by [[Oswaldo Cruz Foundation]].<ref>{{cite news | vauthors = Walsh N, Shelley J, Duwe E, Bonnett W |date=27 July 2020 |title=The world's hopes for a coronavirus vaccine may run in these health care workers' veins |url=https://edition.cnn.com/2020/07/27/americas/brazil-covid-19-sinovac-vaccine-intl/index.html |publisher=CNN |location=São Paulo |access-date=3 August 2020 |name-list-style=vanc |archive-date=3 August 2020 |url-status=live|archive-url=https://web.archive.org/web/20200803211040/https://edition.cnn.com/2020/07/27/americas/brazil-covid-19-sinovac-vaccine-intl/index.html }}</ref>}}<ref name="NCT04400838">{{#invoke:Cite web| |title=Investigating a Vaccine Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04400838 |website=[[ClinicalTrials.gov]] |id=NCT04400838 |date=26 May 2020 |access-date=14 July 2020 |archive-date=11 October 2020 |url-status=live|archive-url=https://web.archive.org/web/20201011084750/https://clinicaltrials.gov/ct2/show/NCT04400838/ }}</ref><ref name="EudraCT-2020-001228-32">{{#invoke:Cite web| |url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB |title=A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 |website=EU Clinical Trials Register |publisher=European Union |id=[[EudraCT]] 2020-001228-32 |date=21 April 2020 |access-date=3 August 2020 |archive-date=5 October 2020 |url-status=live|archive-url=https://web.archive.org/web/20201005201654/https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB }}</ref><ref name="ISRCTN89951424">{{cite journal |title=A Phase III study to investigate a vaccine against COVID-19 |website=ISRCTN |id=ISRCTN89951424 |doi=10.1186/ISRCTN89951424 |date=26 May 2020 | vauthors = O'Reilly P | doi-access=free }}</ref><br />[[Universityოქსფორდის of Oxfordუნივერსიტეტი]], [[AstraZeneca]], [[Coalition for Epidemic Preparedness Innovations|CEPI]]